viewCytoDyn Inc.

CytoDyn releases video highlighting the science of how leronlimab works in immuno-oncology

The company said the video captures the potential benefits of leronlimab in the tumor microenvironment

CytoDyn Inc. - CytoDyn releases a video highlighting the science of how leronlimab works in immuno-oncology
CytoDyn Chief Medical Officer Scott A Kelly said Leronlimab’s safety profile and potential synergistic effects with oncology treatments may be an "exciting opportunity" within immuno-oncology

CytoDyn Inc (OTCQB:CYDY) has released an animation video to show how its investigational new drug, leronlimab, works to support immuno-oncology, the development of treatments that take advantage of the body's immune system to fight cancer.

The Vancouver, Washington-based company is currently exploring the effectiveness of leronlimab in treating several immuno-oncology indications, including metastatic triple-negative breast cancer. It has also treated the first breast cancer patient in its Phase 2 basket trial for 22 solid cancer tumors.

The phase Phase 2 basket trial is aimed at nearly 22 different solid tumor cancers — including melanoma, brain-glioblastoma, throat, lung, stomach, colon carcinoma, breast, testicular, ovarian, uterine, pancreas, bladder, among other indications — and includes 30 patients with CCR5+ locally advanced or metastatic solid tumors. 

READ: CytoDyn partners with Mexican health authorities to conduct trial of leronlimab for critically ill coronavirus patients

Leronlimab was previously granted Fast Track designation by the US Food and Drug Administration (FDA) for its indications as a treatment for metastatic triple-negative breast cancer and as part a combination therapy for HIV-infected patients.

For coronavirus (COVID-19), the FDA has granted a so-called rolling review for the drug as part of its biologics license application submission. 

In a statement on Thursday, CytoDyn said it is “encouraged” by the potential of leronlimab to positively influence the tumor microenvironment by “inhibiting T-reg infiltration, conversion of M2 macrophages (protumor macrophages) into M1 macrophages (antitumor macrophages),” decreasing tumor angiogenesis, and inhibiting metastasis.

“We appreciate the work of Nucleus Medical Media to capture the potential benefits of leronlimab in the tumor microenvironment. The control of the tumor microenvironment is critical in the ultimate determination of clinical patient outcomes. We believe leronlimab may help leverage the immune system’s natural ability to fight cancer," CytoDyn chief medical officer, Scott A Kelly, who also is chairman of the company’s board, said in a statement.

“Leronlimab’s safety profile and potential synergistic effects with current oncology treatments may prove to be an exciting opportunity within immuno-oncology,” he added.

CytoDyn said it has met its 75-patient enrollment target in its Phase 2 clinical trial for COVID-19, a randomized clinical study for mild-to-moderate COVID-19 patients in the US. Also, enrollment continues in its Phase 2b/3 randomized clinical trial for severe and critically ill COVID-19 patients in several hospitals throughout the US.

Contact the author Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: @UttaraProactive

Quick facts: CytoDyn Inc.

Price: 3.4099 USD

Market: OTCQB
Market Cap: $1.94 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...


CytoDyn addresses WSJ & SeekingAlpha articles, calls on investors to pay...

CytoDyn Inc. (OTCQB:CYDY) CEO Nader Pourhassan addresses the recent articles published by the Wall Street Journal and SeekingAlpha, in regards to its participation in Operation Warp Speed. Pourhassan says shareholders should pay attention to the group's fundamentals, adding to 'only buy the...

3 weeks, 6 days ago

2 min read